miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders.

By combining the technology elements of DREAmiR™, miRecule’s ® ARC’s unlock the true potential of RNA therapies to enable patients live a life free from the debilitating syptoms of their disorders.

Oct 4, 2022 · The collaboration will combine miRecule’s anti-DUX4 RNA therapy (discovered through its proprietary DREAmiR platform) with Sanofi’s proprietary muscle-targeted NANOBODY technology to join the two molecules into an ARC utilizing miRecule’s NAVIgGatorTM conjugation and formulation chemistry.

Oct 9, 2024 · miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with …

miRecule, Inc. 704 Quince Orchard Road Gaithersburg, MD 20878. Follow; Follow

miRecule, Inc. is a rapidly growing biotechnology start-up focused on the development of RNA therapeutics to treat a variety of diseases. miRecule’s DREAmiRTM genomics-based discovery platform is designed to create best-in-class RNA therapies, identifying critical RNA targets for drug development in specific subsets of patients that would ...

miRecule, Inc. is a rapidly growing biotechnology start-up focused on the development of RNA therapeutics to treat a variety of diseases. miRecule’s DREAmiR genomics-based discovery platform is designed to create best-in-class RNA therapies, identifying critical RNA targets for drug development in specific subsets of patients that would ...

Jun 28, 2024 · Chicago, May 2024 — miRecule, a cutting-edge startup focused on developing antibody RNA conjugate therapeutics, clinched the top spot at the prestigious MedCity INVEST Biopharma track competition held at the Ritz Carlton in Chicago.

Personal information provided to miRecule through resumes, CVs, or cover letters is provided through an applicant’s own volition. Any information provided (email, phone number, etc.) will be used for the sole purpose of further communication with applicants.

Dr. John Lambert, Ph.D is one of the leading experts in the field of ADC discovery and development. He joined ImmunoGen in 1987 and served as Chief Scientific Officer from 2008 until 2015, and was subsequently Distinguished Research Fellow …